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ABSTRACT
Rac1 GTPase has long been recognized as a critical regulatory protein in 
different cellular and molecular processes involved in cancer progression, including 
acute myeloid leukemia. Here we show the antitumoral activity of ZINC69391 and 
1A-116, two chemically-related Rac1 pharmacological inhibitors, on a panel of four 
leukemic cell lines representing different levels of maturation. Importantly, we 
show that the main mechanism involved in the antitumoral effect triggered by the 
Rac1 inhibitors comprises the induction of the mitochondrial or intrinsic apoptotic 
pathway. Interestingly, Rac1 inhibition selectively induced apoptosis on patient-
derived leukemia cells but not on normal mononuclear cells. These results show 
the potential therapeutic benefits of targeting Rac1 pathway in hematopoietic 
malignancies.
INTRODUCTION
Rho-GTPases are molecular switches that cycle 
between an inactive GDP-bound form and an active 
GTP-bound form. This cycle is closely regulated by 
guanine nucleotide exchange factors (GEFs) that catalyze 
nucleotide exchange and mediate activation [1]; and 
GTPase-activating proteins (GAPs), that stimulate GTP 
hydrolysis and inactivate the GTPase [2]. Only the 
active GTP-bound state binds to downstream effector 
proteins and actively transduces signals [3]. Rac1 is one 
of the most studied members of Rho-GTPases family and 
controls fundamental cellular processes including cell 
proliferation, actin cytoskeleton reorganization, migration, 
cell cycle progression, cell adhesion, differentiation and 
apoptosis [4–6].
Acute myeloid leukemia (AML) is an aggressive 
blood disorder characterized by an accumulation of 
immature hematopoietic stem cells in the bone marrow [7, 
8]. AML is the most common type of leukemia in adults 
with lowest survival rate of all leukemias.
Due to their key role in different cancer types, 
Rho GTPases are attractive and validated targets for 
anticancer therapies [9–11]. Rac1 GTPase acts as 
critical mediator of signaling pathways contributing to 
the interactions of hematopoietic stem cells with their 
microenvironment [12]. This protein is overexpressed 
in primary acute leukemia cells and leukemia stem cells 
compared to normal bone marrow mononuclear cells 
[13–15]. The siRNA-mediated knockdown of Rac1 
expression in leukemia cell lines proved to inhibit cell 
proliferation, migration and colony formation [15]. In 
contrast, overexpression of Rac1 increases cell migration 
and proliferation potential of leukemic cells, which could 
be implicated in leukemia development and progression 
[16, 17]. All this evidence supports the therapeutic 
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potential of target-based therapies against Rac1-GTPase 
in hematological malignancies.
Previously, we identified ZINC69391 and its 
analog 1A-116 as small molecules that inhibited Rac1-
GEF interactions reducing Rac1 activation levels on 
different cancer cells. ZINC69391 was able to inhibit 
cell proliferation, cell cycle progression and migration 
of highly aggressive breast cancer cell lines. Moreover, 
ZINC69391 and 1A-116 inhibited lung metastasis in vivo 
[18]. We also described an antiapoptotic and anti-invasive 
effect of ZINC69391 on glioblastoma cell lines [19].
In the present work we studied the antitumoral 
activity of the pharmacological Rac1 inhibitors, 
ZINC69391 and 1A-116, (Figure 1) in a panel of human 
acute leukemia cell lines, representing different levels of 
maturation. We demonstrate that ZINC69391 treatment 
induced growth inhibition associated to apoptotic cell 
death program activation. This pro-apoptotic activity 
involved a pronounced caspase 3 activation, mitochondrial 
membrane potential loss, sequential caspase 9 and 8 
activation and increase of the phosphorylated fraction 
of Bcl-2. In line with our previous results, 1A-116 
also showed to be a more potent agent on leukemic 
cells. Interestingly, Rac1 inhibition displayed selective 
activity on patient-derived leukemic cells having no 
cytotoxic effect on normal monocytic and lymphocytic 
cells, representing a promising pharmacological and 
selective compound for the treatment of hematological 
malignancies.
RESULTS
ZINC69391 is a small molecule drug that inhibits 
growth of human leukemia cell lines
ZINC69391 is a first generation small molecule 
that was identified as a Rac1-GEF interaction inhibitor, 
using a docking-based virtual library screening approach. 
In previous reports, ZINC69391 was able to inhibit 
several Rac1-GEF interactions, which were associated to 
antiproliferative effects, cell cycle arrest and migration 
inhibition of highly aggressive breast cancer cell lines [18]. 
Moreover, ZINC69391 demonstrated in vivo anti metastatic 
activity in lung and apoptotic induction in glioma cells 
with decreased cell migration and invasion [19]. Based 
on these previous reports we sought to determine whether 
ZINC69391 exhibited activity against cell proliferation 
in vitro on a panel of human acute leukemia cell lines 
with different stages of cell differentiation. Three human 
myeloid leukemia cell lines (U937, HL-60 and KG1A) and 
a leukemia-derived T-cell line (Jurkat cells) were treated 
with ZINC69391 for 48h. Cell growth was inhibited in 
a concentration-dependent manner showing IC50 values 
of micromolar range (Table 1). This result indicates a 
high potency of ZINC69391 as a proliferation inhibitor 
of leukemic cells. Interestingly, Jurkat cells exhibited a 
shift in the concentration-response curve in comparison to 
myeloid lineage, suggesting a lower sensitivity of Jurkat 
cells to ZINC69391 although the maximal response was 
similar to that observed for KG1A.
ZINC69391 treatment increases G2/M 
subpopulation in AML cell lines
Regarding the involvement of Rac1 on cell cycle 
progression we next compared the effects of ZINC69391 
on cell cycle distribution. Synchronized HL-60, U937, 
KG1A and Jurkat cells were treated for 24h with 50 μM 
ZINC69391 and then stained using PI to establish DNA 
content by flow cytometry. The antiproliferative effects 
of ZINC69391 correlated with effects over cell cycle 
progression showing a significant increase in G2/M 
subpopulation for HL-60 and KG1A cell lines (Figure 2). 
Although for U937 and Jurkat cell lines the differences 
were not significant, the same tendency was observed. 
These results are in concordance with several reports 
describing that Rac1 inhibition is associated to a G2/M 
cell cycle arrest [20–22].
Figure 1: Chemical structures of Rac1 inhibitors (A) Chemical structure of ZINC69391 (C14H15F3N5; molecular weight, 310.303). (B) 
Chemical structure of 1A-116 analog (C16H16F3N3; molecular weight, 307.31).
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ZINC69391 triggers apoptosis on human acute 
leukemic cells
To further investigate the molecular mechanisms 
underlying antiproliferative effects of ZINC69391 on 
leukemia cells, different apoptotic markers were evaluated. 
First, we analyze the change in annexin V/PI positive 
staining of cells by flow cytometry. Using the same cell 
panel described before, we found that treatment with 50 
μM ZINC69391 for 24h led to a significant increase in 
apoptotic cells (Annexin V positive) in HL-60, U937 
and KG1A cell lines (Figure 3A), while no significant 
change was observed for Jurkat cells. Interestingly, these 
results correlate with an increased sub G0/G1 population 
(apoptotic cells) observed in cell cycle analysis for all cell 
lines tested (Figure 3B). It is worth noting that ZINC69391 
did not promote necrosis at the time tested in any of the 
cell lines.
Since caspase 3 is a terminal effector in the 
apoptotic cascade that is activated after proteolytic 
cleavage, we assessed cleaved caspase 3 by western blot 
after ZINC69391 treatment. After 24h incubation with 
ZINC69391, cells exhibited an increase in both active 
fractions of caspase 3 (Figure 4A). Next, we confirmed 
caspase 3 activation by a colorimetric assay using 
ZINC69391 50 μM and 100 μM for different incubation 
periods (Figure 4B). Incubation with ZINC69391 
augmented the enzymatic activity of caspase 3 in a 
concentration dependent manner, in agreement with the 
results obtained by western blot (Figure 4A). These results 
showed that ZINC69391 triggered apoptosis in human 
acute leukemic cells, as confirmed by three different 
approaches.
Rac1 inhibitor ZINC69391 modifies NF-κB 
transcriptional activity
To further evaluate the implications of Rac1 
inhibition, we studied the effect of ZINC69391 on NF-
κB transcriptional activity. NF-kappaB is a transcription 
factor that plays a crucial role in cell cycle progression and 
expression of anti-apoptotic genes, having Rac1 a major 
role in its activation [23, 24]. We selected Interleukin 8 
(IL-8), a gene transactivated by NF-κB, as a downstream 
target to be evaluated by qPCR in HL-60 and Jurkat 
cell lines [25, 26]. We found that ZINC69391 treatment 
potentiated twice IL-8 mRNA levels in Jurkat cells, while 
in HL-60, mRNA levels were profoundly diminished 
(Figure 5A). This opposed response to NF-κB-induced 
transcriptional activity after ZINC69391 treatment reflects 
the differential sensitivity observed for these cells lines in 
previous assays.
ZINC69391 pro-apoptotic activity involves 
alterations of mitochondrial effectors and its 
integrity
The proteins of Bcl-2 family are regulators of several 
mechanisms associated to cell death such as mitochondrial 
permeabilization, apoptosis amplification [27] and more 
recently, the modulation of cellular redox metabolism 
[28]. Regarding the fact that Bcl-2 family members 
function downstream of Rac1 [29] and considering their 
participation on mitochondrial membrane integrity, we 
also investigated the effect of ZINC69391 on Bcl-2, 
Bcl-xL and Mcl-1 mRNA levels by qPCR. After 12h of 
ZINC69391 treatment, HL-60 cells showed a significant 
decrease only in Mcl-1 levels, while Jurkat cells exhibited 
increased mRNA levels of all proteins evaluated (Figure 
6A).
Since Bcl-2 family proteins function is also 
regulated by post translational modifications, we 
decided to evaluate the protein Bcl-2 by western blot. 
Immunoblotting showed a shift on Bcl-2 mobility for 
HL-60, KG1A and Jurkat cells after 12h of ZINC69391 
treatment compared to control cells (Figure 6B). Shifts like 
that were previously associated to Bcl-2 phosphorylated 
fractions which are a common mechanism of modulation 
of Bcl-2 activity [30, 31].
In the mitochondrial or intrinsic pathway of 
apoptosis, caspase activation is dependent of outer 
mitochondrial membrane permeabilization induced by 
pro-apoptotic members of the Bcl-2 family. In order 
to gain further insight into the mechanism of apoptosis 
exerted by ZINC69391, we evaluated the effect of the 
compound on mitochondrial membrane permeability 
(MMP). Dyes such as 3,3′-dihexyloxa-dicarbocyanine 
(DiOC6) are lipophilic cationic probes that are taken up by 
living cells and accumulate in intact mitochondria. When 
mitochondrial membranes are damaged or leaky there is a 
loss of DiOC6 fluorescence intensity. Based on that, it can 
serve as marker of mitochondrial membrane integrity [32]. 
We treated the cell lines with ZINC69391 for different 
time periods and then measured DiOC6 fluorescence by 
FACS. As seen in Figure 6C (left), U937 cells treated with 
ZINC69391 show an increase in MMP in a time dependent 
manner, having its maximum effect at 4h post-treatment. 
Interestingly, this same effect was observed in HL-60 
and KG1A cells, while Jurkat showed a modest and not 
significant increase in MMP process (Figure 6C right). We 
Table 1: IC50 values of ZINC69391 in human acute leukemia cell lines
Cell line U937 HL-60 KG1A Jurkat
IC50μM (CI95) 43,4 (38-49) 41,7 (37,4-46,6) 54,1 (41-71) 41 (29,6-58,5)
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next evaluated the effect of ZINC69391 on pro-caspase 
9 activation, a relevant initiator caspase associated to the 
mitochondrial or intrinsic pathway. As shown in Figure 
7A, ZINC69391 induced an increase in cleaved caspase 9 
in the acute myeloid cell lines, having no clear effect on 
T-cell derived Jurkat cells. This increase is time dependent, 
starting at 4h after treatment and showing a significant 
increase of caspase 9 activity around 6h post-treatment.
We also studied the effect of ZINC69391 on caspase 
8 activation using caspase 8 specific antibodies. As 
expected, its activation was also time-dependent showing 
a significant increase in caspase 8 cleavage at later time 
points compared to caspase 9 activity (Figure 7B). These 
results are consistent with a caspase 8 cleavage as a 
consequence of advanced stages of the apoptotic program 
initiated by mitochondrial damage instead of an activation 
of death receptor pathway [33, 34].
ZINC69391 displays no proapoptotic effect on 
human lymphocytic and monocytic normal cells
We next sought to determine whether this 
proapoptotic effect of ZINC69391 was selective for cancer 
cells. Normal peripheral blood mononuclear cells (PBMC) 
from healthy donors were stained using annexinV/PI. As 
shown in Figure 8, after 24h treatment with ZINC69391 
50 μM or 100 μM, there were no significant changes in 
cell viability compared to vehicle-treated cells. In the same 
way, Phytohemagglutinin A activated (i.e. proliferating) 
lymphocytes were also not sensitive to ZINC69391 action.
Interestingly, the concentration of ZINC69391 that 
induced the highest apoptotic effect in leukemic cells 
failed to induce cytotoxicity on PBMC from healthy 
donors.
ZINC69391-derived 1A-116 analog displayed 
increased potency in leukemic cell lines and 
showed a profound pro-apoptotic effect on 
patient-derived leukemic cells
We have previously described the development of 
1A-116, a novel analog of ZINC69391, which showed 
to be more potent than the parental compound in 
glioma and aggressive breast cancer models [18, 19]. 
To evaluate the effect of 1A-116 on cell proliferation in 
leukemic cells, we measured cell viability by the MTS 
metabolic assay. 1A-116 inhibited cell proliferation in 
a concentration-dependent manner, showing enhanced 
efficacy in Jurkat cells reaching a 100% inhibition in 
cell proliferation. Moreover, in the more undifferentiated 
cellular models of myeloid leukemia (HL-60 and 
KG1A), 1A-116 showed a left shift in the concentration 
response curves indicating an increased potency in its 
antiproliferative activity (Figure 9A).
Figure 2: Cell cycle distribution after ZINC69391 treatment in human acute leukemia cell lines.  Synchronized G0/G1 
cells were exposed to ZINC69391 50 μM or to 0.05% (v/v) DMSO, vehicle control group for 24h. Cell cycle distribution was calculated as 
described in Material and Methods. Data represent the mean ± SD (n > 3). *p< 0.05.
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Figure 3: Pro-apoptotic activity of ZINC69391 in human acute leukemia cell lines. (A) Starved cells were exposed to 
ZINC69391 50 μM or to 0.05% (v/v) DMSO, vehicle control group. After 24h of treatment, cells were analyzed by flow cytometry to 
detect exposed phosphatidylserine by annexin V binding. The graphic shows the different cell subpopulations according to the annexin V/PI 
staining pattern: cells labeled with only annexin V (early apoptosis), cells labeled with annexin V and PI (late apoptosis), and cells labeled 
only with PI (necrotic cells). Data is presented as mean ± SD from four independent experiments. *p<0.05; **p<0.01. (B) Representative 
histogram of leukemic cell lines where the subpopulation hypodiploid subG0/G1 is observed.
Figure 4: Caspase 3 activation in apoptosis induced by ZINC69391.  (A) The cleavage of caspase 3 was evaluated by western 
blot. Equal amounts of protein were subjected to SDS–PAGE and western blot with anti-caspase 3. Data are representative of at least three 
independent experiments. (B) Cells were treated with ZINC69391 in the indicated concentrations and time, and caspase 3 protease activity 
was measured using a colorimetric kit as described in Materials and Methods and expressed as OD405nm values. Data are presented as 
mean ± SD from four independent experiments. *p<0.05; **p<0.01; ***p<0.005.
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Additionally, we compared the effect of both 
compounds on Rac1 activation levels. As seen in Figure 
9B, ZINC69391 and 1A-116 treatment on HL-60 cells 
decreased Rac1-GTP levels. Interestingly, 1A116 showed 
a more potent effect on Rac1 activation compared to 
ZINC69391 parental drug. This effect is in line with 
previous our reports in other cancer models.
Finally, we evaluated the effect of 1A116 compound 
on recently established patient-derived leukemic cell 
cultures. For this purpose, we used two independent 
primary cultures of leukemic cells from lymphocytic 
lineage. One of these cell cultures is TLX+, while the 
other is TLX-. TLX is a an oncogene and its expression 
defines a distinct subgroup of T cell acute lymphoblastic 
leukemia, being TLX1+ tumors prone to aneuploidy 
and showing marked defects in the activation of normal 
mitotic checkpoints [35]. We evaluated the effect of 50 
μM 1A-116 treatment in both cell cultures. Interestingly, 
1A-116 treatment induced apoptosis in both cell types, 
being TLX- cells more sensitive. This effect is shown in 
Figure 9C, where TLX- cells had a significant increase 
in the apoptotic population after 24h treatment, while a 
similar effect is shown for TLX+ cells after 48h treatment. 
It is important to mention that TLX+ cells treated for 24h 
showed no apoptotic effect (data not shown).
DISCUSSION
Rac1 has long been recognized as an important 
regulatory protein in different physiological and disease 
processes [36]. We have previously shown the effect of 
Rac1 inhibition by ZINC69391 and 1A-116 in breast 
cancer and glioma models, but Rac1 represents attractive 
innovative target for many other types of cancers [37]. The 
present work shows the effect of ZINC69391 and 1A-116 
compound in hematopoietic malignancies. The rationale 
that led us to explore this cancer indication was based in 
evidence showing that Rac1 is over-expressed in leukemia 
patients [15, 36]. Moreover, CD34+ cells isolated from 
patients with AML showed high levels of activated Rac1 
and this signaling pathway has been identified as a critical 
mediator of stem cell and stroma interaction [10, 12]. 
Additionally, loss of Rac1 impairs engraftment, homing, 
localization and proliferation of hematopoietic stem cells/
progenitor cells [38].
Ours results show that ZINC69391 is able to reduce 
the activation of Rac1 GTPase in HL-60 cells. This effect 
correlates with the programmed cell death induction 
observed as consequence of growth cell inhibition on 
a panel of human leukemic cells. These results are in 
line with previous reports that use dominant negative 
constructs, siRNA strategies as well as other Rac1 
inhibitors to suppress Rac1 activity [12, 36, 39].
Remarkably, ZINC69391 showed low micromolar 
IC50 values in all cell lines tested, independently on 
their hematopoietic cell differentiation stage or lineage. 
In fact, previous reports showed that leukemic cells with 
MLL (Mixed Lineage Leukemia) rearrangements were 
specifically vulnerable to Rac1 inhibition, while cell lines 
such as HL-60, U937 and Jurkat were more resistant [10, 
Figure 5: Real time PCR evaluation of Interleukin 8 mRNA levels in leukemic cells treated with ZINC69391. HL-60 
and Jurkat cells were incubated with 50 μM of ZINC69391 or 0.05% (v/v) DMSO vehicle control group for 12h. IL-8 mRNA 
levels were quantified by qPCR as described in the methods section. Results are mean ± SD of at least three independent 
experiments performed in triplicates. **p < 0.01; ***p<0.005.
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40]. Our data show that ZINC69391 treatment inhibited 
cell proliferation of leukemic cells despite the fact that all 
cell lines tested here do not harbor MLL rearrangements. 
These results show a differential in vitro potency 
compared to other Rac1 inhibitors and this could be a 
key issue for in vivo efficacy in further animal studies. 
It could be interesting to determine the effect of this 
new family of Rac1 inhibitors in leukemic cells bearing 
MLL rearrangements. We would expect higher anticancer 
potency against this type of tumors.
We next studied the underlying mechanisms of 
the antiproliferative effect induced by ZINC69391. 
In previous work on solid tumors, we identified that 
ZINC69391 antiproliferative effect was mainly due 
to cell cycle arrest in G0/G1 and apoptosis induction 
[19]. Interestingly, cell cycle analysis in leukemic cells 
Figure 6: ZINC69391 effect on anti-apoptotic Bcl-2 family proteins and mitochondrial membrane permeability 
(MMP).  (A) HL-60 and Jurkat cells were incubated with 50 μM of ZINC69391 or 0.05% (v/v) DMSO vehicle control group for 12h. Bcl-
2, Bcl-xL and Mcl-1 mRNA levels were quantified by qPCR as described in the methods section. Results are mean ± SD of at least three 
independent experiments performed in triplicates. **p<0.01; ***p<0.005 (B) Analysis of MMP alteration at indicated times for U937 (left 
panel) and HL-60, KG1a and Jurkat (right panel) cell lines. Cells treated with 50 μM of ZINC69391 or 0.05% (v/v) DMSO vehicle control 
group, were evaluated for changes in fluorescence intensity of DiOC6 probe by flow cytometry. The bar graph shows differences among 
treatment times (n=4) *p<0.05; **p<0.01; ***p<0.005. (C). Representative graphic shows Bcl-2 protein assessment by Western blot. Equal 
amounts of protein were subjected to SDS–PAGE and western blot using anti-Bcl-2 protein antibody. *p<0.05; **p<0.01; ***p<0.005.
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Figure 7: ZINC69391 stimulated activation of caspases 8 and 9.  (A) Cells were treated with ZINC69391 for the indicated time, 
and caspase 9 protease activity was measured using a colorimetric kit as described in Materials and Methods and expressed as OD405nm 
values. Data are presented as mean ± SD from three independent experiments; *p<0.05; **p<0.01; ***p<0.005. (B). Cleavage of caspase 
8 was evaluated by Western blot. Equal amounts of protein were subjected to SDS–PAGE and western blot using anti-caspase 8 antibody. 
Blots were subjected to densitometry analysis using ImageJ software. Data are presented as mean ± SD respect to control of at least three 
independent experiments. *p<0.05; **p<0.01; ***p<0.005.
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lines showed a G2/M arrest, which correlated with the 
antiproliferative activity exerted by the compound. It has 
been described that Rac1 inactivation is associated with 
altered cell cycle progression by impaired centrosomal 
activation in G2 phase [20, 21]. Additionally, the 
appearance of a sub-G0 population of cells in these 
DNA fluorescence histograms suggests the detection 
of apoptotic cells on the basis of their reduced DNA 
content. In this regard, ZINC69391 induced apoptosis in 
all the cell lines evaluated. The stimulation of apoptosis 
exerted by ZINC69391 was caspase-dependent, since 
pro-caspase 3 cleavage was observed in a concentration 
dependent manner. Interestingly, although Jurkat cells 
did not show changes in annexin V staining after 50μM 
ZINC69391 treatment, they did show an increase in 
cleaved caspase 3 at high concentration (100 μM). 
These results show that lymphoid Jurkat cells are more 
resistant to ZINC69391-induced apoptosis than AML 
cells.
We found that ZINC69391 induces the activation 
caspase 9, triggering the intrinsic pathway of apoptosis. 
Only after caspase 9 stimulation, caspase 8 activation is 
evidenced. Additionally, the treatment of leukemia cells 
with ZINC69391 resulted in mitochondrial membrane 
function loss and an increase in Bcl-2 phosphorylation 
in a time dependent manner, both events associated to 
apoptosis induction.
One possible mechanism contributing to the pro-
apoptotic effect of Rac1 inhibition in leukemic cells may 
be through the Rac1-dependent regulation of NF-κB 
transcriptional activity. Rac1 can mediate the activation of 
several oncogenic pathways, including NF-κB activation 
[41, 42]. NF-κB can, in turn, induce the transcription of 
various proteins, being a central regulator of lymphocyte 
proliferation, survival and development [43]. We observed 
that ZINC69391 provoked a significant reduction of 
mRNA levels of IL-8 on HL-60 cells, suggesting that 
IL-8 expression may be Rac1-dependent in HL-60 cells; 
while this effect was not shown by Jurkat cells. These 
results are in line with the observation that Jurkat cells 
are more resistant to ZINC69391 treatment, and it may be 
due to a compensation mechanism associated to Jurkat´s 
PTEN null phenotype. The tumor suppressor gene PTEN 
(phosphatase and tensin homolog) is an important negative 
regulator of PI3K-Akt pathway. PTEN null cells maintain 
PI3K signaling constitutively activated, increasing cancer 
susceptibility, tumor cell proliferation and drug resistance 
in multiple hematological malignancies [44, 45]. Since 
NF-κB transcriptional activity is controlled by parallel 
pathways, including PI3K/Akt, IL-8 increased levels 
in Jurkat cells could be related to this characteristic 
phenotype.
Evasion of apoptosis is primarily driven by 
upregulation from pro-survival members of the Bcl-2 
family, especially Bcl-2, Bcl-xL and Myeloid cell leukemia 
1 (Mcl-1) [46]. Indeed, we show that pharmacological 
inhibition of the Rac1 signaling pathway by ZINC69391 
in HL-60 cells inhibited Mcl-1 expression, showing no 
effect on Bcl-2 and Bcl-xL expression. Interestingly, the 
same treatment on Jurkat cells shows a significant increase 
in the expression of these three pro-survival proteins. This 
upregulation may be a part of a resistance mechanism, 
where Jurkat cells overexpress the pro-survival proteins 
to overcome, without success, Rac1 inhibition. In this 
sense, several reports indicate that Bcl-2 and Bcl-xL [47, 
48] enhanced expression is mediated through a NF-κB-
dependent mechanism, while Mcl-1 is a downstream target 
of PI3K signaling pathway [49]. Interestingly, despite 
the fact that we observed diverse cell responses and 
sensitivities to Rac1 inhibition in different hematopoietic 
Figure 8: Compound selectivity assessed in normal peripheral blood mononuclear cells (PBMC).  Phosphatidylserine 
exposure was measured by annexin V binding assay in monocytes, unstimulated lymphocytes or phytohemagglutinin A activated (i.e. 
proliferating) lymphocytes after 24h treatment with ZINC69391 at the indicated concentrations or to 0.05% (v/v) DMSO vehicle control 
group. Data represent the mean ± SD (n > 3). ns. No significant differences (ns).
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Figure 9: 1A-116 is a more potent Rac1 inhibitor and shows proapoptotic activity on patient-derived leukemia cells. 
(A) Cells were cultured in the presence of increasing concentrations (100 nM to 300 μM) of ZINC69391 or 1A-116 for 48h. Cell viability 
was determined by MTS assay and reported as a percent of proliferation inhibition respect to vehicle treated cells (n>3). (B) HL-60 cells 
were treated with 50 μM ZINC69391 and 50 μM 1A-116 for 24h and cell lysates were subjected to a pull down assay. Both drugs reduced 
Rac1-GTP levels, being 1A-116 more potent than the parental drug (n=3 independent experiments). (C) Patient-derived leukemia cells 
were treated with 50 μM 1A-116 for 24h. Apoptotic cell population was analyzed using annexinV staining by flow cytometry. *p<0.05; 
**p<0.01.
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cell lineages, in all cell lines tested we ultimately observed 
increased apoptosis after ZINC69391 treatment.
Although Rac1 has proven to be an interesting 
molecular target in AML and other myeloproliferative 
diseases [10, 50], Rac1 also plays an important role 
in normal hematopoietic cell homeostasis [12, 51]. In 
this sense, ZINC69391 treatment did not promote cell 
death program on normal peripheral blood mononuclear 
cells, including Phytohemagglutinin A activated (i.e. 
proliferating) lymphocytes. Moreover, we show that 1A-
116 compound significantly induces apoptosis in two 
patient-derived leukemic cells. Thus, we can speculate that 
Rac1 signaling in leukemia cancer cells mainly contributes 
to the acquisition of the transformed phenotype, while 
normal mononuclear cells do not rely entirely on this 
pathway and are able to compensate Rac1 inhibition. 
These results are also in line with a previous report, where 
Rac1 protein levels in leukemia patients were significantly 
higher than that in normal donors and this overexpression 
contributes to cell proliferation and leukemia progression 
[15]. In agreement, it has been previously suggested that 
transformed cells become addicted to Rac1 signaling for 
survival and leukemia maintenance [16].
It is important to note, that in this work most 
experiments were performed using 50 μM and 100 μM 
ZINC69391. Although this compound was used to study 
the mechanism of action and the effect on cancer cells of a 
novel Rac1 inhibitor family, we are aware of its limitations 
for further clinical development. For this reason, we tested 
the effect of the ZINC69391-derived analog 1A-116. This 
analog shares high structural homology with ZINC69391 
compound and both have shown to exert their biological 
effect by the same mechanism of action in different cancer 
models. In line with previous published data in solid 
tumors models, 1A-116 showed increased potency in AML 
cell, showing an enhanced reduction of Rac1-GTP levels 
compared to the parental drug. This molecular effect is 
reflected in an augmented antiproliferative activity as well.
In agreement with the relevant role of Rac1 
signaling pathway in several malignancies, the inhibitory 
effects displayed for ZINC69391 and 1A-116 highlight 
their potential as new therapeutic agents. In this sense it 
would be very interesting to evaluate these inhibitors in 
Kaposi´s sarcoma, where Rac1 seems to play an important 
role in tumorigenesis and it is overexpressed in AIDS-
associated Kaposi's Sarcoma lesions [52]. Our evidence 
suggests that the use of Rac1 inhibitors could be a useful 
tool for novel therapeutic management of these tumors.
Finally, Rac1 signal transduction is an interesting 
molecular target in acute leukemia and its inhibition by 
pharmacological agents such as ZINC69391 and 1A-116 
induces the cell death program. This effect was exclusively 
observed in cancer cell lines and patient-derived cells 
when compared to normal PBMC. Future in vivo studies 
using pharmacological agents targeting Rac1 pathway in 
combination with other therapeutic agents could point out 
a new treatment option for leukemic malignancies.
MATERIALS AND METHODS
Reagents and antibodies
ZINC69391 (Figure 1A) was purchased from 
Enamine database and solubilized in dimethyl sulfoxide 
(DMSO). 1A-116 (Figure 1B) was synthesized as reported 
and solubilized in aqueous vehicle. Stock solutions were 
stored at -20°C until use and final concentration for 
each experiment comprised less than 0.1%. Cell culture 
medium RPMI-1640 and antibiotics were obtained 
from Sigma Chemical Company (St. Louis, MO) and 
FBS from Natocor (Argentina). Anti-Bcl-2 and anti-
αTubulin antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA); anti-caspase 8 
was from Cell Signaling Technologies (Massachusetts, 
USA) and anti-caspase 3 antibody from Neuromics 
(Edina, MN, USA). Anti-CD5 Monoclonal Antibody 
(UCHT2), PE-Cyanine7, was obtained from eBioscience. 
A horseradish peroxidase-conjugated goat anti-mouse and 
anti-rabbit were used as the secondary antibody (Vector 
and Santa Cruz Biotechnology, respectively). Annexin 
V-FITC/PI apoptosis detection kit was obtained from 
BD Biosciences Pharmingen (San Diego, CA, USA) and 
caspase 9 substrate was obtained from AnaSpec (Fremont, 
CA, USA).
Cell culture and synchronization
Human leukemia cell lines U937, HL-60, KG1A 
and Jurkat were obtained from American Type Culture 
Collection (ATCC) and grown in RPMI-1640 medium 
(Sigma Aldrich Co.) supplemented with 10% fetal bovine 
serum (FBS) and 50 μg/ml Gentamicin in a humidified 5% 
CO2 atmosphere at 37°C.
Peripheral blood mononuclear cells (PBMC) were 
obtained from heparinized samples of healthy donors 
isolated by centrifugation on Ficoll-Hypaque. Cells were 
cultured at 37°C in a humidified atmosphere with 5% 
CO2 in RPMI-1640 medium, supplemented with 10% 
FBS and 50 μg/ml Gentamicin. For activation of the 
peripheral T cells, 2.0x106 cells/ml were incubated with 
Phytohemagglutinin A at a concentration of 1.0 μg/ml for 
48h before treatment with ZINC69391. Blood samples 
from normal volunteers were obtained after written 
informed consent in accordance with the Declaration of 
Helsinki. These studies were approved by the institutional 
review board of the National Academy of Medicine of 
Buenos Aires.
Primary T-ALL cells of the TLX1+ and TLX– 
subtypes were kindly provided by Dr. Xosé Bustelo. 
Cells were processed for genetic and flow cytometry 
characterization and rapidly stored in liquid nitrogen. For 
expansion, cells were thawed, cultured in the presence 
of feeder layers of OP9-DL1 cells in MEM α containing 
IL-7 (5 ng/mL, Peprotech), Flt3L (5 ng/mL, Peprotech) 
and 20% FBS for 48h, and injected into sublethally-
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irradiated (2 Gy) 6- to 8-week-old NOD-Scid IL2rgnull 
mice (NSG, Jackson Laboratory). Engrafted T-ALL blasts 
(CD5+CD7+CD45+) were collected by preparative flow 
cytometry from the thymi, spleens, and bone marrows of 
the recipient mice 10 weeks later. Cells were then frozen 
in liquid nitrogen and, when needed, cultured on OP9-DL1 
cells as indicated above.
The TLX1+ T-ALL cells were TCRα/β–, TCRγ/δ–, 
CD45++, CD34–, TdT+ (58%), icCD3+, mCD3low, 
CD7++, CD5++, CD2+ (78%), CD4+, CD8–, CD1a+ 
(90%), CD10+, CD13–, CD33–, CD56–, CD123– and 
CD117–.
The TLX– T-ALL cells were mTCRα/β+ (100%), 
CD4+ (31%), CD8–, CD5+, CD7+, CD45+, IL7R–, 
ICN1–, and TLX–. In addition to the cytogenetic 
analyses, the TLX status of primary tumor cells was 
confirmed by qRT-PCR both before and after expansion in 
immunocompromised mice.
For cell synchronization at G0/G1, cells were serum-
starved for 7h at 37°C and thereafter relieved into cell 
cycle by addition of 10% FBS. Before seeding, viability 
of cell lines and PBMC were tested by Trypan Blue assay. 
Cells were used only if viability was higher than 90%.
MTS assay
Cell proliferation was determined by a colorimetric 
assay using CellTiter 96 AQueous Non-Radioactive Cell 
Proliferation Assay (Promega, USA) according to the 
manufacturer’s instructions. For MTS assay, cells growing 
in exponential phase were seeded at 2.0x104 cells/well in a 
96-well plate and incubated in an atmosphere of 5% CO2 at 
37°C. Cells were exposed to serial dilutions of ZINC69391, 
1A-116 or 0.1% (v/v) DMSO (vehicle control group). After 
incubation for 48h, 20 μl of MTS was added to each well 
and further incubated for 2h at 37°C. The absorbance was 
measured at 490 nm using the FlexStation 3 microplate 
reader (Molecular Devices Inc., USA).
Half maximal inhibitory concentration 50 (IC50) 
values were calculated with GraphPad Prism software 
(GraphPad Software Inc., USA) using the sigmoidal dose-
response function and expressed as IC50 (μM). Assays 
were carried out in triplicate and at least three independent 
experiments were conducted.
Analysis of cell cycle phases distribution by flow 
cytometry
Synchronized cell populations were treated with 50 
μM of ZINC69391 or 0.05% (v/v) DMSO (vehicle) for 
15h. After treatment, cells were harvested, washed with 
ice-cold PBS, fixed overnight by addition of 70% (v/v) 
ethanol and stored at -20°C for a minimum of 24h. On 
the day of flow cytometry analysis, cell suspensions were 
washed with ice-cold PBS and re-suspended in 50 μl 
RNase A (100 μg/ml) at room temperature for 15 min.
Propidium Iodide was added to a final concentration 
of 20 μg/ml and incubated in dark at room temperature 
for 20 min. Cell cycle phase distributions were analyzed 
by FACS Scan Flow Cytometer (Beckton-Dickinson CA, 
USA). Data from at least three independent experiments 
were analyzed using ModFit software (VeritySoftware 
House Inc., Topsham, ME, USA) to determine the 
fractions of cells in the subG0/G1, G0/G1, S and G2/M 
phases from cell cycle distribution.
Determination of apoptosis markers
Annexin V/PI binding assay
Starved cell populations were plated in 12-well 
plates at a density of 5.0x105 cells/ml and cultured with 50 
μM of ZINC69391 or vehicle (0.05% DMSO) in complete 
medium for 24h. After washing with ice-cold PBS, 
2.0x105 cells were incubated with FITC-labeled annexin 
V and PI according to the manufacturer’s instructions 
(BD Biosciences Pharmingen, San Diego, CA, USA) 
and analyzed by a FACS Scan Flow Cytometer (Becton-
Dickinson CA, USA).
Patient-derived T-ALL cells were treated with 
50 μM 1A-116 for 24h, stained using the annexin V–
fluorescein propidium isothiocyanate detection kit 
(Immunostep), and apoptosis determined in the population 
of CD5 positive cells using flow cytometry.
Annexin V is a calcium-dependent phospholipid-
binding protein that has an affinity for phosphatidylserine 
(PS) which in early-stage apoptosis becomes translocated 
to the extracellular membrane leaflet. In late stage 
apoptosis, the cell membrane loses integrity thereby 
allowing annexin V to also access PS in the interior of the 
cell. In these cases the addition of a viability dye such as 
propidium iodide (PI) can be used to resolve these late-
stage apoptotic and necrotic cells [53].
Caspase 3 activity assay
Cells growing in exponential phase were seeded in 
6-well plates and treated with 50 and 100 μM ZINC69391 
or vehicle (DMSO) in complete medium during 12h and 
24h. Cells were then harvested and processed according 
to CASP3C caspase 3 colorimetric assay kit (Sigma 
Chemical Co. St. Louis, MO, USA). Absorbance at 405 
nm, due to hydrolysis of the peptide substrate acetyl-
Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA), was 
measured using the FlexStation 3 microplate reader 
(Molecular Devices Inc., USA) and caspase 3 activity was 
expressed as OD405 value.
RT-PCR and quantitative real-time PCR
Total RNA was isolated from HL-60 and Jurkat 
cells using Quick-Zol reagent (Kalium Technologies) 
following the manufacturer’s instructions. For the first-
strand cDNA synthesis, 1 μg of total RNA was reverse-
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transcribed using the High Capacity cDNA Reverse 
Transcription kit (AB) with random primers. Quantitative 
real-time PCR (qPCR) was performed in triplicate on the 
Rotor Gene Q cycler (Qiagen) using the resulting cDNA, 
the HOT FIREPol EvaGreen qPCR Mix Plus (Solis 
Biodyne) for product detection, and the following primers: 
Human Bcl-2 (B-cell lymphoma 2; NM_000633.2) 
forward, 5′-GGATGCCTTTGTGGAACTGTAC-3′ 
and reverse, 5′- TTCACTTGTGGCCCAGATAGG-3′; 
Bcl-xL (B-cell lymphoma extra large; NM_138578.2) 
forward, 5′-GGTCGCATTGTGGCCTTTTT-3′ and 
reverse, 5′- GCTCTAGGTGGTCATTCAGGT-3′; 
Mcl-1 (Myeloid cell leukemia 1; NM_021960.4) 
forward, 5′- GCTTCGGAAACTGGACATCAA-3′ 
and reverse, 5′- CCAGTTTGTTACGCCGTCG-3′; 
IL-8 (Interleukin 8; NM_000584) forward 5′-5´-CT
GCGCCAACACAGAAATTA-3´-3′ and reverse 
5´-ATTGCATCTGGCAACCCTAC-3´; and human β-Actin 
(βAct) forward, 5′-GGACTTCGAGCAAGAGATGG-3′ 
and reverse 5′-AGCACTGTGTTGGCGTACAG-3′. The 
cDNA was amplified by 45 cycles of denaturing (10 s at 
95 °C), annealing (10 s at 60 °C), and extension (10 s at 72 
°C) steps. The specificity of each primer set was monitored 
by analyzing the dissociation curve, and the relative GILZ, 
THBD or SLC19A2 mRNA quantification was performed 
using the comparative ΔΔCt method using β-Actin as the 
housekeeping gene.
Mitochondrial membrane permeability 
evaluation (MMP)
In order to assess mitochondrial membrane potential 
in U937 cells, 6.0x105 cells/ml were seeded in 48-well 
plates and treated with 50 μM of ZINC69391 at different 
times. After treatment, cells were harvested, centrifuged 
and incubated in the dark with 10 nM of the probe DiOC6 
in RPMI-1640 for 20 min. Fluorescence was analyzed by 
flow cytometry (ʎex/ʎem = 488/530nm) using FACS Scan 
Flow Cytometer (Becton-Dickinson CA, USA) and results 
were analyzed with ModFit software (Verity). According 
to the results obtained for U937 cell line, HL-60, KG1A 
and Jurkat were also evaluated for 3, 5 and 7h with 50 μM 
of ZINC69391.
Preparation of cell lysates and Western blot 
analysis
Cells were washed in PBS and lysed in 50 mM Tris–
HCl pH 6.8, 2% SDS, 100 mM 2-mercaptoethanol, 10% 
glycerol and 0.05% bromophenol blue and sonicated to 
shear DNA. Cellular proteins from total cell lysates (20 
μg) were electrophoresed on 8–15% SDS polyacrylamide 
gel and transferred to nitrocellulose membranes. Blots 
were blocked with 5% non-fat powdered milk in TBS 
containing 0.05% Tween-20 and probed with the 
indicated primary antibodies followed by horseradish-
peroxidase-conjugated secondary antibodies. Reactivity 
was developed by enhanced chemiluminescence (ECL) 
according the manufacturer’s instructions (Amersham Life 
Science, England).
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